[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche ’s Corporate Executive Committee

Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments:Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based in South San Francisco, will become a member of the enlarged Corporate Executive Committee. Both will report to the Roche Group CEO, Thomas Schinecker, when he takes over the role in March 2023.“I am excited that we can appoint a global strategic leader like Teresa Graham as our new Pharmaceuticals CEO. She brings a deep understanding of our business and is well-positioned for success.” Severin Schwan says: “Levi Garraway is an excellent addition to the executive committee. I have hi gh regard for his thoughtful, scientific, and data-driven approach to our late stage portfolio and his dedication to bringing innovative medicines to patients.”“Teresa Graham is a great leader with strong followership. She brings strategic and scientific acumen with an excellent track record of performance. I am pleased that a person of her caliber will be our new Pharma CEO.” Thomas Schinecker says: “Levi Garraway is an impressive clinician and scie ntist and I am excited to have him become ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news